Related Experiment Video
Updated: Feb 25, 2026
Animal Model of Implant-Associated Infections in Mice
Published on: June 27, 2025
Animal models
1Institute for Biological Sciences, National Research Council of Canada, Ottawa.
Abstract:
Animal models of cerebral ischaemia mimic at best less than 25% of all strokes. Compounds which prove efficacious in animal models should, therefore, only be expected to improve outcome in a quarter of all strokes. If trials for acute stroke are to succeed, stroke subgroups represented by the animal models should be targeted. For the other subgroups, e.g. lacunar stroke, appropriate animal models need to be developed. Moreover, thrombolysis should be included in animal models because it is likely to be used as a first line treatment for ischaemic stroke and any future therapeutics will need to be compatible with it.
Insights
Current animal models for cerebral ischemia only represent a fraction of human stroke cases. Future stroke therapeutics development requires targeted models and inclusion of thrombolysis for better clinical translation.
Area of Science:
- Neuroscience
- Translational Medicine
- Pharmacology
Background:
- Cerebral ischemia animal models inadequately represent the heterogeneity of human stroke, mimicking less than 25% of cases.
- This discrepancy limits the predictive value of preclinical studies for stroke therapeutics.
Purpose of the Study:
- To highlight the limitations of current animal models in cerebral ischemia research.
- To propose strategies for improving the translational relevance of preclinical stroke studies.
Main Methods:
- Analysis of the representativeness of existing animal models for human stroke subtypes.
- Review of current therapeutic strategies and their potential integration into preclinical models.
Main Results:
- Existing animal models of cerebral ischemia represent a limited spectrum of human stroke conditions.
- Efficacy in these models may only translate to a small proportion of stroke patients.
Conclusions:
- Targeting specific stroke subgroups represented by current animal models is crucial for successful clinical trials.
- Development of novel animal models for underrepresented stroke types, such as lacunar stroke, is necessary.
- Incorporating thrombolysis into animal models is essential for evaluating future ischemic stroke therapeutics due to its clinical use.
